retatrutide triple agonist obesity trial ⭐️topline results from TRIUMPH-1, a Phase 3 clinical evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon hormone receptor agonist, in adults with or “overweight” Michael Weintraub, MD on X:

Metabolic and Endocrine Risks Hypoglycemia (CRITICAL RISK): The most serious acute risk is low blood sugar

Find your recommended protein intake Calculate your recommended daily protein needs for weight loss, maintaining weight, or building muscle, based on your current weight and activity level

Fatima A, Maryam A, Nadeem MS, Asmat KN

Commonly reported side effects in the Phase 2 trial included: Nausea (the most frequently reported adverse effect) Vomiting Diarrhoea Constipation Decreased appetite Abdominal discomfort or bloating Eructation (belching) The majority of participants who discontinued treatment did so due to gastrointestinal side effects, underscoring the importance of the slow titration schedule used in trials